Latest Breaking News On - Director don - Page 4 : comparemela.com

Penumbra, Inc (NYSE:PEN) Shares Acquired by Braun Stacey Associates Inc

Penumbra, Inc (NYSE:PEN) Shares Acquired by Braun Stacey Associates Inc
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesDonw kassingArani boseRedmile groupCanaccord genuity groupPenumbra incMorgan stanleyBraun stacey associates incRoyal bankJpmorgan chase coQuadrature capital ltdManufacturers life insurance companySecurities exchange commissionBraun stacey associatesFree reportStacey associates

Penumbra, Inc (NYSE:PEN) Stake Increased by Braun Stacey Associates Inc

Penumbra, Inc (NYSE:PEN) Stake Increased by Braun Stacey Associates Inc
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesPiper sandlerDonw kassingJohanna robertsPenumbra incSecurities exchange commissionLazard asset managementRoyal bankBraun stacey associates incJpmorgan chase coFinancial gravity asset management incCanaccord genuity groupHoldings channelBraun stacey associatesFree reportStacey associates

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Free Report) in a research report released on Tuesday morning, Benzinga reports. HC Wainwright currently has a $7.00 price objective on the stock. Separately, Cantor Fitzgerald reissued an overweight rating and set a $6.00 price target on shares of Lineage Cell […]

United statesDonm baileyVanguard group incAmerica corpGeode capital managementSecurities exchange commissionBlackrock incLineage cell therapeutics incCantor fitzgeraldLineage cell therapeuticsFree reportCell therapeuticsDirector broadwood partnersExchange commissionDirector donStreet corp

HC Wainwright Reiterates Buy Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They currently have a $7.00 price objective on the stock. Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $6.00 price target on shares of […]

United statesDonm baileyDefender capitalSecurities exchange commissionBarclays plcAmerican international group incRaffles associatesFort sheridan advisorsCantor fitzgeraldLineage cell therapeutics incLineage cell therapeutics company profileLineage cell therapeuticsGet free reportCell therapeuticsDirector broadwood partnersExchange commission

Lineage Cell Therapeutics, Inc (NYSEAMERICAN:LCTX) Director Don M Bailey Buys 96,155 Shares

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Get Free Report) Director Don M. Bailey acquired 96,155 shares of the stock in a transaction that occurred on Thursday, February 8th. The stock was purchased at an average price of $1.04 per share, with a total value of $100,001.20. Following the transaction, the director now owns 158,801 shares […]

United statesDonm baileyLineage cell therapeutics incRathbones groupDeutsche bankSecurities exchange commissionLineage cell therapeutics company profileSg americas securitiesVanguard group incCantor fitzgeraldNorthern trust corpLineage cell therapeuticsGet free reportDirector donExchange commissionCell therapeutics